Median (range) protein expression and localisation in patients treated with sulindac and placebo
| Sulindac | Placebo | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before | After | Before | After | ||||||
| bcl-2 | Base | 3 (2–3) | 3 (2–3) | 2.5 (2–3) | 2.5 (2–3) | ||||
| Surface | 1 (1–2) | 1 (1–2) | 1.5 (1–2) | 1 (1) | |||||
| bax | Base | 2 (2) | 2 (1–2) | 1.5 (1–2) | 1.5 (1–2) | ||||
| Surface | 3 (3–4) | 3 (2–4) | 2.5 (2–3) | 2.5 (2–3) | |||||
| p21 | Base | 1 (1) | 1 (1) | 1 (1) | 1 (1) | ||||
| Surface | 3.5 (2–4) | 3 (3–4) | 3 (3–4) | 3 (3–4) | |||||
| p53 | Base | 1 (1) | 1 (1) | 1 (1) | 1 (1) | ||||
| Surface | 1 (1) | 1 (1) | 1 (1) | 1 (1) | |||||
p21 was only expressed in the upper third of the crypt and at the luminal surface; no p53 expression was seen. No statistical differences were noted by Wilcoxon paired rank sum test.